

Supplemental Appendix

Prioritizing additional data collection to reduce decision uncertainty in the HIV/AIDS response in 6 US cities: a value of information analysis

This supplementary appendix provides supporting information to the manuscript and presents the process of the expected value of partially perfect information (EVPPI) result validation and model tuning for the artificial neural network (ANN) model, organized as follows:

- Figure A1 presents the schematic diagram for the structure of the dynamic compartmental HIV transmission model we applied in this value of information analysis. It shows the 19 health states that individuals progress through in the model.
- Figure A2 presents the flowchart depicting the process of the EVPPI analysis.
- Figure A3 shows the result validation comparing the EVPPI estimates for the parameter group of HIV transmission probabilities per homosexual partnership using the ANN model and the generalized additive model (GAM) model.
- Figure A4 shows the probabilities of computing combination strategies representing the highest values, by cost-effectiveness threshold.
- Figure A5 shows the composition of the highest-valued combination strategies, by cost-effectiveness threshold.
- Figure A6 shows the city-level expected value of perfect information, by cost-effectiveness threshold.
- Figure A7 shows the estimated EVPPI for each individual model parameter using GAM at a threshold of \$100,000/QALY, ranked by EVPPI. We then identified and grouped those with the greatest EVPPI as key groups of model parameters for further metamodel analysis with the ANN model.
- Table A1 presents the description, values and uncertainty distributions for the key groups of model parameters that were found to be the most influential on decision uncertainty for each city.

Result validation and model tuning

Given the novelty of the ANN metamodel, we performed several checks to ensure the validity of EVPPI estimates from this model for the key groups of parameters. First, given the extensive evidence for the precision and validation of the GAM approach, we treated the EVPPI estimates from GAM as the “gold standard” and compared the estimated EVPPI for HIV transmission probabilities per homosexual partnership (three parameters in the group) based on both the ANN and GAM approach (Figure A3). Second, following best practices, we defined the lower bound of the EVPPI for a given parameter group as the maximum EVPPI value estimated for each single parameter (using GAM) within that group, while the upper bound was defined as the city-level EVPI which measured the decision uncertainty from all model parameters jointly. We compared the ANN metamodel results to ensure the EVPPI estimates for all the identified key groups of parameters fell within the two bounds. Third, the variance of model predictions and resulted EVPPI from the ten repeated estimations can indicate good model fit, i.e. large variance indicates poor fit. We hand tuned the model by varying the number of hidden layers and hidden nodes until the estimated variance was within a reasonable range while the mean ± 1.96 x standard deviation of the estimated values was inside the two bounds. Figure A3 shows the result validation for the parameter group of HIV transmission probabilities per homosexual partnership.




Figure A1. Model schematic diagram




Figure A2. Flowchart depicting the process of the expected value of partial perfect information analysis.

PSA: probabilistic sensitivity analysis; EVPI: expected value of perfect information; EVPPI: expected value of partial perfect information; GAM: generalized additive model; ANN: artificial neural network. * Key groups of parameters were defined by having at least one parameter whose $EVPPI > (0.05 \times EVPI)$ and groupings were based on as per suggested in practice.




Figure A3. Result validation for the parameter group of HIV transmission probabilities per homosexual partnership

The error bars represent the mean ± 1.96 x standard deviation of the estimated values from the ten repeated estimations; two dashed lines represent the corresponding lower and upper bounds. ANN: artificial neural network; GAM: generalized additive model




Figure A4. Probabilities of computing combination strategies representing the highest values, by cost-effectiveness threshold.

QALY: quality-adjusted life year




Figure A5. The composition of the highest-valued combination strategies, by cost-effectiveness threshold.

MOUD: Medication for opioid use disorder; PrEP: Pre-exposure prophylaxis; MSM: Men who have sex with men; ER: Hospital emergency room; EMR: Electronic medical records; ART: antiretroviral therapy.




Figure A6. The city-level expected value of perfect information, by cost-effectiveness threshold.



Figure A7. Distribution of the expected value of partial perfect information (EVPPI) for each individual model parameter.

Table A1. The key groups of model parameters most influential on decision uncertainty for each city

CITY	Atlanta	Baltimore	Los Angeles	Miami	New York City	Seattle
MORTALITY RATES FOR PLHIV						
Monthly mortality rate for PLHIV (CD4: 200-499), except PWID						
PE	6.39E-04	6.39E-04	6.39E-04	6.39E-04	6.39E-04	6.39E-04
Distribution	Pert(1.13, 4.02)	Pert(1.13, 4.02)	Pert (1.13, 4.02)	Pert (1.13, 4.02)	Pert (1.13, 4.02)	Pert (1.13, 4.02)
Monthly mortality rate for PLHIV (CD4<200), except PWID						
PE	0.0072	0.0072	0.0072	0.0072	0.0072	0.0072
Distribution	Pert (3.21, 4.53)	Pert (3.21, 4.53)	Pert (3.21, 4.53)	Pert (3.21, 4.53)	Pert (3.21, 4.53)	Pert (3.21, 4.53)
Multiplier of mortality rate for PLHIV that inject drugs (CD4: 200-499)						
PE	1.59	1.59	1.59	1.59	1.59	1.59
Distribution	Pert (1.16, 4.06)	Pert (1.16, 4.06)	Pert (1.16, 4.06)	Pert (1.16, 4.06)	Pert (1.16, 4.06)	Pert (1.16, 4.06)
Multiplier of mortality rate for PLHIV that inject drugs (CD4<200)						
PE	1.59	1.59	1.59	1.59	1.59	1.59
Distribution	Pert (1.16, 4.06)	Pert (1.16, 4.06)	Pert (1.16, 4.06)	Pert (1.16, 4.06)	Pert (1.16, 4.06)	Pert (1.16, 4.06)
Monthly mortality rate for PLHIV on ART (CD4>500), Male White PWID						
PE	0.000868	0.000798	0.000786	0.000868	0.000798	0.000748
Distribution	ln (-7.13, 0.246)	ln (-7.13, 0.246)	ln (-7.15, 0.288)	ln (-7.13, 0.246)	ln (-7.13, 0.246)	ln (-7.20, 0.316)
Monthly mortality rate for PLHIV on ART (CD4>500), Male White MSM						
PE	0.000303	0.000277	0.000273	0.000303	0.000277	0.000259
Distribution	ln (-8.10, 0.184)	ln (-8.19, 0.167)	ln (-8.21, 0.196)	ln (-8.10, 0.184)	ln (-8.19, 0.167)	ln (-8.26, 0.236)
Monthly mortality rate for PLHIV on ART (CD4>500), Male White MWID						
PE	0.000693	0.000636	0.000625	0.000693	0.000636	0.000617
Distribution	ln (-7.27, 0.237)	ln (-7.36, 0.221)	ln (-7.38, 0.241)	ln (-7.27, 0.237)	ln (-7.36, 0.221)	ln (-7.39, 0.29)
Monthly mortality rate for PLHIV on ART (CD4>500), Male White HET						
PE	0.000380	0.000348	0.000343	0.000380	0.000348	0.000314
Distribution	ln (-7.88, 0.234)	ln (-7.96, 0.236)	ln (-7.98, 0.279)	ln (-7.88, 0.234)	ln (-7.96, 0.236)	ln (-8.07, 0.304)
Monthly mortality rate for PLHIV on ART (CD4>500), Male Black PWID						
PE	0.000759	0.000699	0.000688	0.000759	0.000699	0.000630
Distribution	ln (-7.18, 0.204)	ln (-7.27, 0.204)	ln (-7.28, 0.27)	ln (-7.18, 0.204)	ln (-7.27, 0.204)	ln (-7.37, 0.3)
Monthly mortality rate for PLHIV on ART (CD4>500), Male Black MSM						
PE	0.000265	0.000242	0.000239	0.000265	0.000242	0.000218
Distribution	ln (-8.24, 0.198)	ln (-8.32, 0.193)	ln (-8.34, 0.244)	ln (-8.24, 0.198)	ln (-8.32, 0.193)	ln (-8.43, 0.287)
Monthly mortality rate for PLHIV on ART (CD4>500), Male Black MWID						
PE	0.000606	0.000556	0.000548	0.000606	0.000556	0.000519
Distribution	ln (-7.41, 0.248)	ln (-7.49, 0.243)	ln (-7.51, 0.277)	ln (-7.41, 0.248)	ln (-7.49, 0.243)	ln (-7.56, 0.338)
Monthly mortality rate for PLHIV on ART (CD4>500), Male Black HET						
PE	0.000332	0.000305	0.000301	0.000332	0.000305	0.000264
Distribution	ln (-8.01, 0.207)	ln (-8.10, 0.204)	ln (-8.11, 0.257)	ln (-8.01, 0.207)	ln (-8.10, 0.204)	ln (-8.24, 0.303)
Monthly mortality rate for PLHIV on ART (CD4>500), Male Hispanic PWID						
PE	0.000439	0.000403	0.000398	0.000439	0.000403	0.000376
Distribution	ln (-7.73, 0.272)	ln (-7.82, 0.274)	ln (-7.83, 0.292)	ln (-7.73, 0.272)	ln (-7.82, 0.274)	ln (-7.89, 0.351)
Monthly mortality rate for PLHIV on ART (CD4>500), Male Hispanic MSM						
PE	0.000153	0.000140	0.000138	0.000153	0.000140	0.000130

<i>Distribution</i>	ln (-8.78, 0.265)	ln (-8.87, 0.228)	ln (-8.89, 0.292)	ln (-8.78, 0.265)	ln (-8.87, 0.228)	ln (-8.95, 0.307)
Monthly mortality rate for PLHIV on ART (CD4>500), Male Hispanic MWID						
<i>PE</i>	0.000351	0.000321	0.000316	0.000351	0.000321	0.000310
<i>Distribution</i>	ln (-7.96, 0.315)	ln (-8.04, 0.294)	ln (-8.06, 0.34)	ln (-7.96, 0.315)	ln (-8.04, 0.294)	ln (-8.08, 0.372)
Monthly mortality rate for PLHIV on ART (CD4>500), Male Hispanic HET						
<i>PE</i>	0.000192	0.000176	0.000174	0.000192	0.000176	0.000158
<i>Distribution</i>	ln (-8.56, 0.295)	ln (-8.65, 0.266)	ln (-8.66, 0.327)	ln (-8.56, 0.295)	ln (-8.65, 0.266)	ln (-8.75, 0.333)
Monthly mortality rate for PLHIV on ART (CD4>500), Female White PWID						
<i>PE</i>	0.000673	0.000616	0.000606	0.000673	0.000616	0.000597
<i>Distribution</i>	ln (-7.30, 0.267)	ln (-7.39, 0.241)	ln (-7.41, 0.288)	ln (-7.30, 0.267)	ln (-7.39, 0.241)	ln (-7.42, 0.307)
Monthly mortality rate for PLHIV on ART (CD4>500), Female White HET						
<i>PE</i>	0.000294	0.000269	0.000264	0.000294	0.000269	0.000250
<i>Distribution</i>	ln (-8.13, 0.232)	ln (-8.22, 0.228)	ln (-8.24, 0.263)	ln (-8.13, 0.232)	ln (-8.22, 0.228)	ln (-8.29, 0.294)
Monthly mortality rate for PLHIV on ART (CD4>500), Female Black PWID						
<i>PE</i>	0.000587	0.000539	0.000531	0.000587	0.000539	0.000502
<i>Distribution</i>	ln (-7.44, 0.217)	ln (-7.53, 0.226)	ln (-7.54, 0.282)	ln (-7.44, 0.217)	ln (-7.53, 0.226)	ln (-7.6, 0.309)
Monthly mortality rate for PLHIV on ART (CD4>500), Female Black HET						
<i>PE</i>	0.000257	0.000235	0.000232	0.000257	0.000235	0.000211
<i>Distribution</i>	ln (-8.27, 0.182)	ln (-8.36, 0.19)	ln (-8.37, 0.265)	ln (-8.27, 0.182)	ln (-8.36, 0.19)	ln (-8.46, 0.297)
Monthly mortality rate for PLHIV on ART (CD4>500), Female Hispanic PWID						
<i>PE</i>	0.000341	0.000311	0.000307	0.000341	0.000311	0.000300
<i>Distribution</i>	ln (-7.98, 0.289)	ln (-8.07, 0.286)	ln (-8.09, 0.318)	ln (-7.98, 0.289)	ln (-8.07, 0.286)	ln (-8.11, 0.356)
Monthly mortality rate for PLHIV on ART (CD4>500), Female Hispanic HET						
<i>PE</i>	0.000149	0.000136	0.000134	0.000149	0.000136	0.000126
<i>Distribution</i>	ln (-8.81, 0.274)	ln (-8.90, 0.251)	ln (-8.92, 0.302)	ln (-8.81, 0.274)	ln (-8.90, 0.251)	ln (-8.98, 0.328)
Monthly mortality rate for PLHIV on ART (CD4: 200-499), Male White PWID						
<i>PE</i>	0.00132	0.00140	0.00165	0.00132	0.00140	0.00137
<i>Distribution</i>	ln (-6.63, 0.191)	ln (-6.57, 0.186)	ln (-6.41, 0.204)	ln (-6.63, 0.191)	ln (-6.57, 0.186)	ln (-6.6, 0.223)
Monthly mortality rate for PLHIV on ART (CD4: 200-499), Male White MSM						
<i>PE</i>	0.000595	0.000628	0.000739	0.000595	0.000628	0.000613
<i>Distribution</i>	ln (-7.43, 0.14)	ln (-7.37, 0.151)	ln (-7.21, 0.145)	ln (-7.43, 0.14)	ln (-7.37, 0.151)	ln (-7.4, 0.183)
Monthly mortality rate for PLHIV on ART (CD4: 200-499), Male White MWID						
<i>PE</i>	0.000936	0.000985	0.001158	0.000936	0.000985	0.000951
<i>Distribution</i>	ln (-6.97, 0.198)	ln (-6.92, 0.187)	ln (-6.76, 0.192)	ln (-6.97, 0.198)	ln (-6.92, 0.187)	ln (-6.96, 0.23)
Monthly mortality rate for PLHIV on ART (CD4: 200-499), Male White HET						
<i>PE</i>	0.000844	0.000896	0.001054	0.000844	0.000896	0.000882
<i>Distribution</i>	ln (-7.08, 0.179)	ln (-7.02, 0.186)	ln (-6.85, 0.208)	ln (-7.08, 0.179)	ln (-7.02, 0.186)	ln (-7.03, 0.203)
Monthly mortality rate for PLHIV on ART (CD4: 200-499), Male Black PWID						
<i>PE</i>	0.00107	0.00113	0.00133	0.00107	0.00113	0.00104
<i>Distribution</i>	ln (-6.84, 0.158)	ln (-6.78, 0.16)	ln (-6.62, 0.192)	ln (-6.84, 0.158)	ln (-6.78, 0.16)	ln (-6.86, 0.226)
Monthly mortality rate for PLHIV on ART (CD4: 200-499), Male Black MSM						
<i>PE</i>	0.000481	0.000507	0.000597	0.000481	0.000507	0.000469
<i>Distribution</i>	ln (-7.64, 0.155)	ln (-7.59, 0.163)	ln (-7.42, 0.172)	ln (-7.64, 0.155)	ln (-7.59, 0.163)	ln (-7.67, 0.21)
Monthly mortality rate for PLHIV on ART (CD4: 200-499), Male Black MWID						

<i>PE</i>	0.000758	0.000796	0.000936	0.000758	0.000796	0.000728
<i>Distribution</i>	ln (-7.18, 0.206)	ln (-7.14, 0.193)	ln (-6.97, 0.223)	ln (-7.18, 0.206)	ln (-7.14, 0.193)	ln (-7.22, 0.266)
Monthly mortality rate for PLHIV on ART (CD4: 200-499), Male Black HET						
<i>PE</i>	0.000682	0.000723	0.000851	0.000682	0.000723	0.000674
<i>Distribution</i>	ln (-7.29, 0.14)	ln (-7.23, 0.158)	ln (-7.07, 0.196)	ln (-7.29, 0.14)	ln (-7.23, 0.158)	ln (-7.3, 0.205)
Monthly mortality rate for PLHIV on ART (CD4: 200-499), Male Hispanic PWID						
<i>PE</i>	0.000730	0.000768	0.000904	0.000730	0.000768	0.000733
<i>Distribution</i>	ln (-7.22, 0.196)	ln (-7.17, 0.185)	ln (-7.01, 0.213)	ln (-7.22, 0.196)	ln (-7.17, 0.185)	ln (-7.22, 0.256)
Monthly mortality rate for PLHIV on ART (CD4: 200-499), Male Hispanic MSM						
<i>PE</i>	0.000328	0.000344	0.000405	0.000328	0.000344	0.000329
<i>Distribution</i>	ln (-8.02, 0.195)	ln (-7.98, 0.177)	ln (-7.81, 0.191)	ln (-8.02, 0.195)	ln (-7.98, 0.177)	ln (-8.02, 0.226)
Monthly mortality rate for PLHIV on ART (CD4: 200-499), Male Hispanic MWID						
<i>PE</i>	0.000518	0.000540	0.000636	0.000518	0.000540	0.000512
<i>Distribution</i>	ln (-7.57, 0.239)	ln (-7.52, 0.219)	ln (-7.36, 0.25)	ln (-7.57, 0.239)	ln (-7.52, 0.219)	ln (-7.58, 0.261)
Monthly mortality rate for PLHIV on ART (CD4: 200-499), Male Hispanic HET						
<i>PE</i>	0.000464	0.000490	0.000577	0.000464	0.000490	0.000473
<i>Distribution</i>	ln (-7.68, 0.188)	ln (-7.62, 0.179)	ln (-7.46, 0.196)	ln (-7.68, 0.188)	ln (-7.62, 0.179)	ln (-7.66, 0.229)
Monthly mortality rate for PLHIV on ART (CD4: 200-499), Female White PWID						
<i>PE</i>	0.00135	0.00142	0.00167	0.00135	0.00142	0.00140
<i>Distribution</i>	ln (-6.61, 0.198)	ln (-6.56, 0.205)	ln (-6.39, 0.238)	ln (-6.61, 0.198)	ln (-6.56, 0.205)	ln (-6.57, 0.249)
Monthly mortality rate for PLHIV on ART (CD4: 200-499), Female White HET						
<i>PE</i>	0.000858	0.000908	0.001068	0.000858	0.000908	0.000903
<i>Distribution</i>	ln (-7.06, 0.187)	ln (-7.00, 0.193)	ln (-6.84, 0.194)	ln (-7.06, 0.187)	ln (-7.00, 0.193)	ln (-7.01, 0.224)
Monthly mortality rate for PLHIV on ART (CD4: 200-499), Female Black PWID						
<i>PE</i>	0.00109	0.00115	0.00135	0.00109	0.00115	0.00107
<i>Distribution</i>	ln (-6.82, 0.169)	ln (-6.77, 0.182)	ln (-6.61, 0.213)	ln (-6.82, 0.169)	ln (-6.77, 0.182)	ln (-6.84, 0.243)
Monthly mortality rate for PLHIV on ART (CD4: 200-499), Female Black HET						
<i>PE</i>	0.000694	0.000732	0.000862	0.000694	0.000732	0.000690
<i>Distribution</i>	ln (-7.27, 0.159)	ln (-7.22, 0.159)	ln (-7.06, 0.196)	ln (-7.27, 0.159)	ln (-7.22, 0.159)	ln (-7.28, 0.216)
Monthly mortality rate for PLHIV on ART (CD4: 200-499), Female Hispanic PWID						
<i>PE</i>	0.000745	0.000780	0.000917	0.000745	0.000780	0.000752
<i>Distribution</i>	ln (-7.2, 0.215)	ln (-7.16, 0.206)	ln (-6.99, 0.236)	ln (-7.2, 0.215)	ln (-7.16, 0.206)	ln (-7.19, 0.26)
Monthly mortality rate for PLHIV on ART (CD4: 200-499), Female Hispanic HET						
<i>PE</i>	0.000473	0.000497	0.000585	0.000473	0.000497	0.000485
<i>Distribution</i>	ln (-7.66, 0.194)	ln (-7.61, 0.183)	ln (-7.44, 0.215)	ln (-7.66, 0.194)	ln (-7.61, 0.183)	ln (-7.63, 0.24)
Monthly mortality rate for PLHIV on ART (CD4<200), Male White PWID						
<i>PE</i>	0.00798	0.00426	0.00566	0.00798	0.00426	0.00575
<i>Distribution</i>	ln (-4.83, 0.15)	ln (-5.46, 0.156)	ln (-5.17, 0.168)	ln (-4.83, 0.15)	ln (-5.46, 0.156)	ln (-5.16, 0.196)
Monthly mortality rate for PLHIV on ART (CD4<200), Male White MSM						
<i>PE</i>	0.00556	0.00295	0.00393	0.00556	0.00295	0.00409
<i>Distribution</i>	ln (-5.19, 0.117)	ln (-5.82, 0.138)	ln (-5.54, 0.125)	ln (-5.19, 0.117)	ln (-5.82, 0.138)	ln (-5.5, 0.154)
Monthly mortality rate for PLHIV on ART (CD4<200), Male White MWID						
<i>PE</i>	0.00891	0.00475	0.00632	0.00891	0.00475	0.00649
<i>Distribution</i>	ln (-4.72, 0.148)	ln (-5.35, 0.148)	ln (-5.06, 0.148)	ln (-4.72, 0.148)	ln (-5.35, 0.148)	ln (-5.04, 0.181)
Monthly mortality rate for PLHIV on ART (CD4<200), Male White HET						

<i>PE</i>	0.00498	0.00265	0.00353	0.00498	0.00265	0.00363
<i>Distribution</i>	ln (-5.3, 0.136)	ln (-5.93, 0.15)	ln (-5.65, 0.16)	ln (-5.3, 0.136)	ln (-5.93, 0.15)	ln (-5.62, 0.169)
Monthly mortality rate for PLHIV on ART (CD4<200), Male Black PWID						
<i>PE</i>	0.00718	0.00384	0.00510	0.00718	0.00384	0.00504
<i>Distribution</i>	ln (-4.94, 0.117)	ln (-5.56, 0.137)	ln (-5.28, 0.168)	ln (-4.94, 0.117)	ln (-5.56, 0.137)	ln (-5.29, 0.191)
Monthly mortality rate for PLHIV on ART (CD4<200), Male Black MSM						
<i>PE</i>	0.00500	0.00266	0.00355	0.00500	0.00266	0.00359
<i>Distribution</i>	ln (-5.3, 0.107)	ln (-5.93, 0.129)	ln (-5.64, 0.14)	ln (-5.3, 0.107)	ln (-5.93, 0.129)	ln (-5.63, 0.166)
Monthly mortality rate for PLHIV on ART (CD4<200), Male Black MWID						
<i>PE</i>	0.00802	0.00428	0.00569	0.00802	0.00428	0.00569
<i>Distribution</i>	ln (-4.83, 0.146)	ln (-5.45, 0.162)	ln (-5.17, 0.167)	ln (-4.83, 0.146)	ln (-5.45, 0.162)	ln (-5.17, 0.198)
Monthly mortality rate for PLHIV on ART (CD4<200), Male Black HET						
<i>PE</i>	0.00449	0.00239	0.00318	0.00449	0.00239	0.00318
<i>Distribution</i>	ln (-5.41, 0.102)	ln (-6.04, 0.122)	ln (-5.75, 0.156)	ln (-5.41, 0.102)	ln (-6.04, 0.122)	ln (-5.75, 0.168)
Monthly mortality rate for PLHIV on ART (CD4<200), Male Hispanic PWID						
<i>PE</i>	0.00616	0.00328	0.00437	0.00616	0.00328	0.00430
<i>Distribution</i>	ln (-5.09, 0.149)	ln (-5.72, 0.16)	ln (-5.43, 0.178)	ln (-5.09, 0.149)	ln (-5.72, 0.16)	ln (-5.45, 0.192)
Monthly mortality rate for PLHIV on ART (CD4<200), Male Hispanic MSM						
<i>PE</i>	0.00429	0.00228	0.00303	0.00429	0.00228	0.00306
<i>Distribution</i>	ln (-5.45, 0.125)	ln (-6.09, 0.145)	ln (-5.8, 0.164)	ln (-5.45, 0.125)	ln (-6.09, 0.145)	ln (-5.79, 0.174)
Monthly mortality rate for PLHIV on ART (CD4<200), Male Hispanic MWID						
<i>PE</i>	0.00688	0.00366	0.00487	0.00688	0.00366	0.00486
<i>Distribution</i>	ln (-4.98, 0.163)	ln (-5.61, 0.172)	ln (-5.32, 0.193)	ln (-4.98, 0.163)	ln (-5.61, 0.172)	ln (-5.33, 0.204)
Monthly mortality rate for PLHIV on ART (CD4<200), Male Hispanic HET						
<i>PE</i>	0.00384	0.00204	0.00272	0.00384	0.00204	0.00271
<i>Distribution</i>	ln (-5.56, 0.135)	ln (-6.19, 0.149)	ln (-5.91, 0.166)	ln (-5.56, 0.135)	ln (-6.19, 0.149)	ln (-5.91, 0.177)
Monthly mortality rate for PLHIV on ART (CD4<200), Female White PWID						
<i>PE</i>	0.00856	0.00457	0.00608	0.00856	0.00457	0.00612
<i>Distribution</i>	ln (-4.76, 0.166)	ln (-5.39, 0.169)	ln (-5.1, 0.181)	ln (-4.76, 0.166)	ln (-5.39, 0.169)	ln (-5.1, 0.208)
Monthly mortality rate for PLHIV on ART (CD4<200), Female White HET						
<i>PE</i>	0.00534	0.00284	0.00378	0.00534	0.00284	0.00386
<i>Distribution</i>	ln (-5.23, 0.142)	ln (-5.86, 0.167)	ln (-5.58, 0.172)	ln (-5.23, 0.142)	ln (-5.86, 0.167)	ln (-5.56, 0.189)
Monthly mortality rate for PLHIV on ART (CD4<200), Female Black PWID						
<i>PE</i>	0.00770	0.00412	0.00547	0.00770	0.00412	0.00537
<i>Distribution</i>	ln (-4.87, 0.132)	ln (-5.49, 0.149)	ln (-5.21, 0.178)	ln (-4.87, 0.132)	ln (-5.49, 0.149)	ln (-5.23, 0.196)
Monthly mortality rate for PLHIV on ART (CD4<200), Female Black HET						
<i>PE</i>	0.00481	0.00256	0.00341	0.00481	0.00256	0.00339
<i>Distribution</i>	ln (-5.34, 0.112)	ln (-5.97, 0.138)	ln (-5.68, 0.161)	ln (-5.34, 0.112)	ln (-5.97, 0.138)	ln (-5.69, 0.179)
Monthly mortality rate for PLHIV on ART (CD4<200), Female Hispanic PWID						
<i>PE</i>	0.00661	0.00352	0.00468	0.00661	0.00352	0.00458
<i>Distribution</i>	ln (-5.02, 0.173)	ln (-5.65, 0.177)	ln (-5.36, 0.199)	ln (-5.02, 0.173)	ln (-5.65, 0.177)	ln (-5.39, 0.204)
Monthly mortality rate for PLHIV on ART (CD4<200), Female Hispanic HET						
<i>PE</i>	0.00412	0.00219	0.00292	0.00412	0.00219	0.00289
<i>Distribution</i>	ln (-5.49, 0.15)	ln (-6.12, 0.159)	ln (-5.84, 0.177)	ln (-5.49, 0.15)	ln (-6.12, 0.159)	ln (-5.85, 0.196)
IMMEDIATE ART ENGAGEMENT						

Probability of direct ART engagement following diagnosis (CD4>500), PWID						
<i>PE</i>	0.226	0.226	0.226	0.226	0.226	0.226
<i>Distribution</i>	Beta (12, 41)	Beta (12, 41)	Beta (12, 41)	Beta (12, 41)	Beta (12, 41)	Beta (12, 41)
Probability of direct ART engagement following diagnosis (CD4>500), MWID						
<i>PE</i>	0.200	0.200	0.200	0.200	0.200	0.200
<i>Distribution</i>	Beta (8, 32)	Beta (8, 32)	Beta (8, 32)	Beta (8, 32)	Beta (8, 32)	Beta (8, 32)
Probability of direct ART engagement following diagnosis (CD4>500), MSM						
<i>PE</i>	0.146	0.349	0.251	0.146	0.349	0.349
<i>Distribution</i>	Beta (66, 387)	Beta (176, 329)	Beta (44, 131)	Beta (66, 387)	Beta (176, 329)	Beta (176, 329)
Probability of direct ART engagement following diagnosis (CD4>500), Male, HET						
<i>PE</i>	0.0893	0.421	0.105	0.0893	0.421	0.421
<i>Distribution</i>	Beta (10, 102)	Beta (40, 55)	Beta (2, 17)	Beta (10, 102)	Beta (40, 55)	Beta (40, 55)
Probability of direct ART engagement following diagnosis (CD4>500), Female, HET						
<i>PE</i>	0.165	0.281	0.269	0.165	0.281	0.281
<i>Distribution</i>	Beta (36, 182)	Beta (27, 69)	Beta (7, 19)	Beta (36, 182)	Beta (27, 69)	Beta (27, 69)
Probability of direct ART engagement following diagnosis (CD4: 200-499), PWID						
<i>PE</i>	0.294	0.294	0.294	0.294	0.294	0.294
<i>Distribution</i>	Beta (15, 36)	Beta (15, 36)	Beta (15, 36)	Beta (15, 36)	Beta (15, 36)	Beta (15, 36)
Probability of direct ART engagement following diagnosis (CD4: 200-499), MWID						
<i>PE</i>	0.333	0.333	0.333	0.333	0.333	0.333
<i>Distribution</i>	Beta (10, 20)	Beta (10, 20)	Beta (10, 20)	Beta (10, 20)	Beta (10, 20)	Beta (10, 20)
Probability of direct ART engagement following diagnosis (CD4: 200-499), MSM						
<i>PE</i>	0.265	0.435	0.321	0.265	0.435	0.435
<i>Distribution</i>	Beta (198, 550)	Beta (237, 308)	Beta (69, 146)	Beta (198, 550)	Beta (237, 308)	Beta (237, 308)
Probability of direct ART engagement following diagnosis (CD4: 200-499), Male, HET						
<i>PE</i>	0.349	0.297	0.246	0.349	0.297	0.297
<i>Distribution</i>	Beta (84, 157)	Beta (35, 83)	Beta (15, 46)	Beta (84, 157)	Beta (35, 83)	Beta (35, 83)
Probability of direct ART engagement following diagnosis (CD4: 200-499), Female, HET						
<i>PE</i>	0.295	0.424	0.425	0.295	0.424	0.424
<i>Distribution</i>	Beta (80, 191)	Beta (39, 53)	Beta (17, 23)	Beta (80, 191)	Beta (39, 53)	Beta (39, 53)
Probability of direct ART engagement following diagnosis (CD4<200), PWID						
<i>PE</i>	0.515	0.515	0.515	0.515	0.515	0.515
<i>Distribution</i>	Beta (34, 32)	Beta (34, 32)	Beta (34, 32)	Beta (34, 32)	Beta (34, 32)	Beta (34, 32)
Probability of direct ART engagement following diagnosis (CD4<200), MWID						
<i>PE</i>	0.545	0.545	0.545	0.545	0.545	0.545
<i>Distribution</i>	Beta (12, 10)	Beta (12, 10)	Beta (12, 10)	Beta (12, 10)	Beta (12, 10)	Beta (12, 10)
Probability of direct ART engagement following diagnosis (CD4<200), MSM						
<i>PE</i>	0.526	0.596	0.644	0.526	0.596	0.596
<i>Distribution</i>	Beta (242, 218)	Beta (115, 78)	Beta (87, 48)	Beta (242, 218)	Beta (115, 78)	Beta (115, 78)
Probability of direct ART engagement following diagnosis (CD4<200), Male, HET						
<i>PE</i>	0.460	0.577	0.701	0.460	0.577	0.577
<i>Distribution</i>	Beta (159, 187)	Beta (45, 33)	Beta (47, 20)	Beta (159, 187)	Beta (45, 33)	Beta (45, 33)
Probability of direct ART engagement following diagnosis (CD4<200), Female, HET						
<i>PE</i>	0.457	0.475	0.486	0.457	0.475	0.475
<i>Distribution</i>	Beta (100, 119)	Beta (28, 31)	Beta (18, 19)	Beta (100, 119)	Beta (28, 31)	Beta (28, 31)

ART ENGAGEMENT: INITIATION						
Monthly ART initiation rate (CD4>500), PWID						
<i>PE</i>	0.0292	0.0292	0.0292	0.0292	0.0292	0.0292
<i>Distribution</i>	Poisson (23) / 789.01	Poisson (23) / 789.01	Poisson (23) / 789.01	Poisson (23) / 789.01	Poisson (23) / 789.01	Poisson (23) / 789.01
Monthly ART initiation rate (CD4>500), MSM						
<i>PE</i>	0.0556	0.0662	0.0853	0.0556	0.0662	0.0662
<i>Distribution</i>	Poisson (280) / 5039.22	Poisson (259) / 3914.6	Poisson (107) / 1254.01	Poisson (280) / 5039.22	Poisson (259) / 3914.6	Poisson (259) / 3914.6
Monthly ART initiation rate (CD4>500), MWID						
<i>PE</i>	0.0690	0.0690	0.0690	0.0690	0.0690	0.0690
<i>Distribution</i>	Poisson (23) / 333.49	Poisson (23) / 333.49	Poisson (23) / 333.49	Poisson (23) / 333.49	Poisson (23) / 333.49	Poisson (23) / 333.49
Monthly ART initiation rate (CD4>500), Male, HET						
<i>PE</i>	0.0425	0.0782	0.0800	0.0425	0.0782	0.0782
<i>Distribution</i>	Poisson (65) / 1529.89	Poisson (38) / 486.15	Poisson (14) / 174.99	Poisson (65) / 1529.89	Poisson (38) / 486.15	Poisson (38) / 486.15
Monthly ART initiation rate (CD4>500), Female, HET						
<i>PE</i>	0.0398	0.0551	0.0866	0.0398	0.0551	0.0551
<i>Distribution</i>	Poisson (120) / 3011.48	Poisson (46) / 834.31	Poisson (17) / 196.37	Poisson (120) / 3011.48	Poisson (46) / 834.31	Poisson (46) / 834.31
Monthly ART initiation rate (CD4: 200-499), PWID						
<i>PE</i>	0.108	0.108	0.108	0.108	0.108	0.108
<i>Distribution</i>	Poisson (30) / 277.24	Poisson (30) / 277.24	Poisson (30) / 277.24	Poisson (30) / 277.24	Poisson (30) / 277.24	Poisson (30) / 277.24
Monthly ART initiation rate (CD4: 200-499), MSM						
<i>PE</i>	0.145	0.149	0.184	0.145	0.149	0.149
<i>Distribution</i>	Poisson (490) / 3375.28	Poisson (271) / 1823.46	Poisson (131) / 710.62	Poisson (490) / 3375.28	Poisson (271) / 1823.46	Poisson (271) / 1823.46
Monthly ART initiation rate (CD4: 200-499), MWID						
<i>PE</i>	0.0573	0.0573	0.0573	0.0573	0.0573	0.0573
<i>Distribution</i>	Poisson (14) / 244.44	Poisson (14) / 244.44	Poisson (14) / 244.44	Poisson (14) / 244.44	Poisson (14) / 244.44	Poisson (14) / 244.44
Monthly ART initiation rate (CD4: 200-499), Male, HET						
<i>PE</i>	0.118	0.189	0.134	0.118	0.189	0.189
<i>Distribution</i>	Poisson (134) / 1135.85	Poisson (74) / 390.83	Poisson (42) / 312.92	Poisson (134) / 1135.85	Poisson (74) / 390.83	Poisson (74) / 390.83
Monthly ART initiation rate (CD4: 200-499), Female, HET						
<i>PE</i>	0.142	0.125	0.149	0.142	0.125	0.125
<i>Distribution</i>	Poisson (175) / 1231.67	Poisson (46) / 368.53	Poisson (21) / 141.34	Poisson (175) / 1231.67	Poisson (46) / 368.53	Poisson (46) / 368.53
Monthly ART initiation rate (CD4<200), PWID						
<i>PE</i>	0.314	0.314	0.314	0.314	0.314	0.314
<i>Distribution</i>	Poisson (31) / 98.84	Poisson (31) / 98.84	Poisson (31) / 98.84	Poisson (31) / 98.84	Poisson (31) / 98.84	Poisson (31) / 98.84
Monthly ART initiation rate (CD4<200), MSM						
<i>PE</i>	0.282	0.257	0.190	0.282	0.257	0.257
<i>Distribution</i>	Poisson (206) / 730.76	Poisson (74) / 287.61	Poisson (43) / 226.7	Poisson (206) / 730.76	Poisson (74) / 287.61	Poisson (74) / 287.61
Monthly ART initiation rate (CD4<200), MWID						
<i>PE</i>	0.240	0.240	0.240	0.240	0.240	0.240
<i>Distribution</i>	Poisson (9) / 37.45	Poisson (9) / 37.45	Poisson (9) / 37.45	Poisson (9) / 37.45	Poisson (9) / 37.45	Poisson (9) / 37.45
Monthly ART initiation rate (CD4<200), Male, HET						
<i>PE</i>	0.262	0.230	0.182	0.262	0.230	0.230

<i>Distribution</i>	Poisson (180) / 686.23	Poisson (28) / 121.9	Poisson (18) / 98.92	Poisson (180) / 686.23	Poisson (28) / 121.9	Poisson (28) / 121.9
Monthly ART initiation rate (CD4<200), Female, HET						
<i>PE</i>	0.296	0.113	0.294	0.296	0.113	0.113
<i>Distribution</i>	Poisson (112) / 378.97	Poisson (24) / 212.4	Poisson (19) / 64.72	Poisson (112) / 378.97	Poisson (24) / 212.4	Poisson (24) / 212.4
ART ENGAGEMENT: RETENTION						
Monthly ART dropout rate (CD4>500), Male White PWID						
<i>PE</i>	0.0191	0.00725	0.00970	0.0191	0.00725	0.00427
<i>Distribution</i>	ln (-3.96, 0.0689)	ln (-4.93, 0.098)	ln (-4.64, 0.1369)	ln (-3.96, 0.0689)	ln (-4.93, 0.098)	Unif (0.0034, 0.0051)
Monthly ART dropout rate (CD4>500), Male White MSM						
<i>PE</i>	0.0132	0.00398	0.00920	0.0132	0.00398	0.00340
<i>Distribution</i>	ln (-4.33, 0.0428)	ln (-5.53, 0.0551)	ln (-4.69, 0.0503)	ln (-4.33, 0.0428)	ln (-5.53, 0.0551)	Unif (0.0027, 0.0041)
Monthly ART dropout rate (CD4>500), Male White MWID						
<i>PE</i>	0.0189	0.00442	0.0114	0.0189	0.00442	0.00340
<i>Distribution</i>	ln (-3.97, 0.0644)	ln (-5.42, 0.0995)	ln (-4.48, 0.1018)	ln (-3.97, 0.0644)	ln (-5.42, 0.0995)	Unif (0.0027, 0.0041)
Monthly ART dropout rate (CD4>500), Male White HET						
<i>PE</i>	0.0133	0.00654	0.00784	0.0133	0.00654	0.00516
<i>Distribution</i>	ln (-4.32, 0.0587)	ln (-5.03, 0.0905)	ln (-4.85, 0.1122)	ln (-4.32, 0.0587)	ln (-5.03, 0.0905)	Unif (0.0041, 0.0062)
Monthly ART dropout rate (CD4>500), Male Black PWID						
<i>PE</i>	0.0182	0.00725	0.00919	0.0182	0.00725	0.00427
<i>Distribution</i>	ln (-4, 0.0607)	ln (-4.93, 0.0901)	ln (-4.69, 0.1454)	ln (-4, 0.0607)	ln (-4.93, 0.0901)	Unif (0.0034, 0.0051)
Monthly ART dropout rate (CD4>500), Male Black MSM						
<i>PE</i>	0.0125	0.00398	0.00871	0.0125	0.00398	0.00703
<i>Distribution</i>	ln (-4.38, 0.0404)	ln (-5.53, 0.061)	ln (-4.74, 0.0942)	ln (-4.38, 0.0404)	ln (-5.53, 0.061)	Unif (0.0056, 0.0084)
Monthly ART dropout rate (CD4>500), Male Black MWID						
<i>PE</i>	0.0180	0.00442	0.0108	0.0180	0.00442	0.00571
<i>Distribution</i>	ln (-4.02, 0.0622)	ln (-5.42, 0.1008)	ln (-4.53, 0.1372)	ln (-4.02, 0.0622)	ln (-5.42, 0.1008)	Unif (0.0046, 0.0069)
Monthly ART dropout rate (CD4>500), Male Black HET						
<i>PE</i>	0.0127	0.00654	0.00743	0.0127	0.00654	0.00516
<i>Distribution</i>	ln (-4.37, 0.0453)	ln (-5.03, 0.0689)	ln (-4.9, 0.1276)	ln (-4.37, 0.0453)	ln (-5.03, 0.0689)	Unif (0.0041, 0.0062)
Monthly ART dropout rate (CD4>500), Male Hispanic PWID						
<i>PE</i>	0.0109	0.00744	0.00595	0.0109	0.00744	0.00475
<i>Distribution</i>	ln (-4.52, 0.0802)	ln (-4.9, 0.0928)	ln (-5.12, 0.1507)	ln (-4.52, 0.0802)	ln (-4.9, 0.0928)	Unif (0.0038, 0.0057)
Monthly ART dropout rate (CD4>500), Male Hispanic MSM						
<i>PE</i>	0.0075	0.00408	0.00564	0.0075	0.00408	0.00340
<i>Distribution</i>	ln (-4.9, 0.0625)	ln (-5.5, 0.0624)	ln (-5.18, 0.0912)	ln (-4.9, 0.0625)	ln (-5.5, 0.0624)	Unif (0.0027, 0.0041)
Monthly ART dropout rate (CD4>500), Male Hispanic MWID						
<i>PE</i>	0.0107	0.00453	0.00698	0.0107	0.00453	0.00340
<i>Distribution</i>	ln (-4.53, 0.0832)	ln (-5.4, 0.1066)	ln (-4.96, 0.1318)	ln (-4.53, 0.0832)	ln (-5.4, 0.1066)	Unif (0.0027, 0.0041)
Monthly ART dropout rate (CD4>500), Male Hispanic HET						
<i>PE</i>	0.0076	0.00670	0.00481	0.0076	0.00670	0.00516
<i>Distribution</i>	ln (-4.89, 0.0696)	ln (-5.01, 0.0727)	ln (-5.34, 0.1294)	ln (-4.89, 0.0696)	ln (-5.01, 0.0727)	Unif (0.0041, 0.0062)

Monthly ART dropout rate (CD4>500), Female White PWID						
<i>PE</i>	0.0191	0.00725	0.00970	0.0191	0.00725	0.00427
<i>Distribution</i>	ln (-3.96, 0.0695)	ln (-4.93, 0.0993)	ln (-4.64, 0.1272)	ln (-3.96, 0.0695)	ln (-4.93, 0.0993)	Unif (0.0034, 0.0051)
Monthly ART dropout rate (CD4>500), Female White HET						
<i>PE</i>	0.0133	0.00654	0.00784	0.0133	0.00654	0.00340
<i>Distribution</i>	ln (-4.32, 0.0601)	ln (-5.03, 0.0889)	ln (-4.85, 0.1169)	ln (-4.32, 0.0601)	ln (-5.03, 0.0889)	Unif (0.0027, 0.0041)
Monthly ART dropout rate (CD4>500), Female Black PWID						
<i>PE</i>	0.0182	0.00725	0.00919	0.0182	0.00725	0.00427
<i>Distribution</i>	ln (-4, 0.055)	ln (-4.93, 0.0924)	ln (-4.69, 0.1437)	ln (-4, 0.055)	ln (-4.93, 0.0924)	Unif (0.0034, 0.0051)
Monthly ART dropout rate (CD4>500), Female Black HET						
<i>PE</i>	0.0127	0.00654	0.00743	0.0127	0.00654	0.00340
<i>Distribution</i>	ln (-4.37, 0.0444)	ln (-5.03, 0.0713)	ln (-4.9, 0.1333)	ln (-4.37, 0.0444)	ln (-5.03, 0.0713)	Unif (0.0027, 0.0041)
Monthly ART dropout rate (CD4>500), Female Hispanic PWID						
<i>PE</i>	0.0109	0.00744	0.00595	0.0109	0.00744	0.00427
<i>Distribution</i>	ln (-4.52, 0.0789)	ln (-4.9, 0.0933)	ln (-5.12, 0.1518)	ln (-4.52, 0.0789)	ln (-4.9, 0.0933)	Unif (0.0034, 0.0051)
Monthly ART dropout rate (CD4>500), Female Hispanic HET						
<i>PE</i>	0.0076	0.00670	0.00481	0.0076	0.00670	0.00340
<i>Distribution</i>	ln (-4.89, 0.0662)	ln (-5.01, 0.075)	ln (-5.34, 0.1309)	ln (-4.89, 0.0662)	ln (-5.01, 0.075)	Unif (0.0027, 0.0041)
Monthly ART dropout rate (CD4: 200-499), Male White PWID						
<i>PE</i>	0.0262	0.00925	0.0128	0.0262	0.00925	0.00427
<i>Distribution</i>	ln (-3.64, 0.0669)	ln (-4.68, 0.1123)	ln (-4.36, 0.1218)	ln (-3.64, 0.0669)	ln (-4.68, 0.1123)	Unif (0.0034, 0.0051)
Monthly ART dropout rate (CD4: 200-499), Male White MSM						
<i>PE</i>	0.0141	0.00661	0.0110	0.0141	0.00661	0.00340
<i>Distribution</i>	ln (-4.26, 0.0449)	ln (-5.02, 0.063)	ln (-4.51, 0.0601)	ln (-4.26, 0.0449)	ln (-5.02, 0.063)	Unif (0.0027, 0.0041)
Monthly ART dropout rate (CD4: 200-499), Male White MWID						
<i>PE</i>	0.0235	0.00703	0.0134	0.0235	0.00703	0.00340
<i>Distribution</i>	ln (-3.75, 0.0691)	ln (-4.96, 0.1073)	ln (-4.31, 0.1129)	ln (-3.75, 0.0691)	ln (-4.96, 0.1073)	Unif (0.0027, 0.0041)
Monthly ART dropout rate (CD4: 200-499), Male White HET						
<i>PE</i>	0.0157	0.00871	0.0105	0.0157	0.00871	0.00516
<i>Distribution</i>	ln (-4.16, 0.0583)	ln (-4.74, 0.0937)	ln (-4.56, 0.1137)	ln (-4.16, 0.0583)	ln (-4.74, 0.0937)	Unif (0.0041, 0.0062)
Monthly ART dropout rate (CD4: 200-499), Male Black PWID						
<i>PE</i>	0.0296	0.00939	0.0143	0.0296	0.00939	0.00427
<i>Distribution</i>	ln (-3.52, 0.054)	ln (-4.67, 0.0893)	ln (-4.25, 0.1435)	ln (-3.52, 0.054)	ln (-4.67, 0.0893)	Unif (0.0034, 0.0051)
Monthly ART dropout rate (CD4: 200-499), Male Black MSM						
<i>PE</i>	0.0159	0.00671	0.0123	0.0159	0.00671	0.00703
<i>Distribution</i>	ln (-4.14, 0.0407)	ln (-5, 0.0679)	ln (-4.4, 0.0986)	ln (-4.14, 0.0407)	ln (-5, 0.0679)	Unif (0.0056, 0.0084)
Monthly ART dropout rate (CD4: 200-499), Male Black MWID						
<i>PE</i>	0.0266	0.00713	0.0150	0.0266	0.00713	0.00571
<i>Distribution</i>	ln (-3.63, 0.0605)	ln (-4.94, 0.1093)	ln (-4.2, 0.1381)	ln (-3.63, 0.0605)	ln (-4.94, 0.1093)	Unif (0.0046, 0.0069)
Monthly ART dropout rate (CD4: 200-499), Male Black HET						
<i>PE</i>	0.0177	0.00884	0.0117	0.0177	0.00884	0.00516

<i>Distribution</i>	ln (-4.03, 0.0401)	ln (-4.73, 0.0707)	ln (-4.45, 0.1183)	ln (-4.03, 0.0401)	ln (-4.73, 0.0707)	Unif (0.0041, 0.0062)
Monthly ART dropout rate (CD4: 200-499), Male Hispanic PWID						
<i>PE</i>	0.0208	0.01032	0.0107	0.0208	0.01032	0.00475
<i>Distribution</i>	ln (-3.87, 0.0685)	ln (-4.57, 0.0891)	ln (-4.54, 0.1428)	ln (-3.87, 0.0685)	ln (-4.57, 0.0891)	Unif (0.0038, 0.0057)
Monthly ART dropout rate (CD4: 200-499), Male Hispanic MSM						
<i>PE</i>	0.0111	0.00737	0.0092	0.0111	0.00737	0.00340
<i>Distribution</i>	ln (-4.5, 0.0544)	ln (-4.91, 0.0678)	ln (-4.69, 0.0816)	ln (-4.5, 0.0544)	ln (-4.91, 0.0678)	Unif (0.0027, 0.0041)
Monthly ART dropout rate (CD4: 200-499), Male Hispanic MWID						
<i>PE</i>	0.0187	0.00784	0.0112	0.0187	0.00784	0.00340
<i>Distribution</i>	ln (-3.98, 0.0759)	ln (-4.85, 0.1083)	ln (-4.49, 0.1306)	ln (-3.98, 0.0759)	ln (-4.85, 0.1083)	Unif (0.0027, 0.0041)
Monthly ART dropout rate (CD4: 200-499), Male Hispanic HET						
<i>PE</i>	0.0124	0.00971	0.00875	0.0124	0.00971	0.00516
<i>Distribution</i>	ln (-4.39, 0.0587)	ln (-4.63, 0.0718)	ln (-4.74, 0.1205)	ln (-4.39, 0.0587)	ln (-4.63, 0.0718)	Unif (0.0041, 0.0062)
Monthly ART dropout rate (CD4: 200-499), Female White PWID						
<i>PE</i>	0.0262	0.00925	0.0128	0.0262	0.00925	0.00427
<i>Distribution</i>	ln (-3.64, 0.0704)	ln (-4.68, 0.1067)	ln (-4.36, 0.1317)	ln (-3.64, 0.0704)	ln (-4.68, 0.1067)	Unif (0.0034, 0.0051)
Monthly ART dropout rate (CD4: 200-499), Female White HET						
<i>PE</i>	0.0157	0.00871	0.0105	0.0157	0.00871	0.00340
<i>Distribution</i>	ln (-4.16, 0.0577)	ln (-4.74, 0.0937)	ln (-4.56, 0.1042)	ln (-4.16, 0.0577)	ln (-4.74, 0.0937)	Unif (0.0027, 0.0041)
Monthly ART dropout rate (CD4: 200-499), Female Black PWID						
<i>PE</i>	0.0296	0.00939	0.0143	0.0296	0.00939	0.00427
<i>Distribution</i>	ln (-3.52, 0.0501)	ln (-4.67, 0.0894)	ln (-4.25, 0.1317)	ln (-3.52, 0.0501)	ln (-4.67, 0.0894)	Unif (0.0034, 0.0051)
Monthly ART dropout rate (CD4: 200-499), Female Black HET						
<i>PE</i>	0.0177	0.00884	0.0117	0.0177	0.00884	0.00340
<i>Distribution</i>	ln (-4.03, 0.0404)	ln (-4.73, 0.072)	ln (-4.45, 0.1165)	ln (-4.03, 0.0404)	ln (-4.73, 0.072)	Unif (0.0027, 0.0041)
Monthly ART dropout rate (CD4: 200-499), Female Hispanic PWID						
<i>PE</i>	0.0208	0.0103	0.0107	0.0208	0.0103	0.00427
<i>Distribution</i>	ln (-3.87, 0.0698)	ln (-4.57, 0.0885)	ln (-4.54, 0.1485)	ln (-3.87, 0.0698)	ln (-4.57, 0.0885)	Unif (0.0034, 0.0051)
Monthly ART dropout rate (CD4: 200-499), Female Hispanic HET						
<i>PE</i>	0.0124	0.0097	0.00875	0.0124	0.0097	0.00340
<i>Distribution</i>	ln (-4.39, 0.0606)	ln (-4.63, 0.0712)	ln (-4.74, 0.1153)	ln (-4.39, 0.0606)	ln (-4.63, 0.0712)	Unif (0.0027, 0.0041)
Monthly ART dropout rate (CD4<200), Male White PWID						
<i>PE</i>	0.0314	0.0129	0.0241	0.0314	0.0129	0.00427
<i>Distribution</i>	ln (-3.46, 0.0993)	ln (-4.35, 0.1465)	ln (-3.73, 0.1711)	ln (-3.46, 0.0993)	ln (-4.35, 0.1465)	Unif (0.0034, 0.0051)
Monthly ART dropout rate (CD4<200), Male White MSM						
<i>PE</i>	0.0188	0.0113	0.0141	0.0188	0.0113	0.00340
<i>Distribution</i>	ln (-3.97, 0.0799)	ln (-4.49, 0.1252)	ln (-4.26, 0.1152)	ln (-3.97, 0.0799)	ln (-4.49, 0.1252)	Unif (0.0027, 0.0041)
Monthly ART dropout rate (CD4<200), Male White MWID						
<i>PE</i>	0.0281	0.0137	0.0208	0.0281	0.0137	0.00340
<i>Distribution</i>	ln (-3.57, 0.0987)	ln (-4.29, 0.1621)	ln (-3.88, 0.1642)	ln (-3.57, 0.0987)	ln (-4.29, 0.1621)	Unif (0.0027, 0.0041)
Monthly ART dropout rate (CD4<200), Male White HET						

<i>PE</i>	0.0210	0.0106	0.0164	0.0210	0.0106	0.00516
<i>Distribution</i>	ln (-3.86, 0.0894)	ln (-4.55, 0.1473)	ln (-4.11, 0.1571)	ln (-3.86, 0.0894)	ln (-4.55, 0.1473)	Unif (0.0041, 0.0062)
Monthly ART dropout rate (CD4<200), Male Black PWID						
<i>PE</i>	0.0405	0.0156	0.0259	0.0405	0.0156	0.00427
<i>Distribution</i>	ln (-3.21, 0.0774)	ln (-4.16, 0.1202)	ln (-3.65, 0.1763)	ln (-3.21, 0.0774)	ln (-4.16, 0.1202)	Unif (0.0034, 0.0051)
Monthly ART dropout rate (CD4<200), Male Black MSM						
<i>PE</i>	0.0243	0.0136	0.0152	0.0243	0.0136	0.00703
<i>Distribution</i>	ln (-3.72, 0.0645)	ln (-4.3, 0.1014)	ln (-4.18, 0.1406)	ln (-3.72, 0.0645)	ln (-4.3, 0.1014)	Unif (0.0056, 0.0084)
Monthly ART dropout rate (CD4<200), Male Black MWID						
<i>PE</i>	0.0363	0.0166	0.0224	0.0363	0.0166	0.00571
<i>Distribution</i>	ln (-3.32, 0.0958)	ln (-4.1, 0.1409)	ln (-3.8, 0.1828)	ln (-3.32, 0.0958)	ln (-4.1, 0.1409)	Unif (0.0046, 0.0069)
Monthly ART dropout rate (CD4<200), Male Black HET						
<i>PE</i>	0.0272	0.0128	0.0177	0.0272	0.0128	0.00516
<i>Distribution</i>	ln (-3.61, 0.0606)	ln (-4.36, 0.1077)	ln (-4.04, 0.1541)	ln (-3.61, 0.0606)	ln (-4.36, 0.1077)	Unif (0.0041, 0.0062)
Monthly ART dropout rate (CD4<200), Male Hispanic PWID						
<i>PE</i>	0.0240	0.0170	0.0176	0.0240	0.0170	0.00475
<i>Distribution</i>	ln (-3.73, 0.1086)	ln (-4.07, 0.1252)	ln (-4.04, 0.2068)	ln (-3.73, 0.1086)	ln (-4.07, 0.1252)	Unif (0.0038, 0.0057)
Monthly ART dropout rate (CD4<200), Male Hispanic MSM						
<i>PE</i>	0.0144	0.0148	0.0103	0.0144	0.0148	0.00340
<i>Distribution</i>	ln (-4.24, 0.0903)	ln (-4.21, 0.1143)	ln (-4.57, 0.1468)	ln (-4.24, 0.0903)	ln (-4.21, 0.1143)	Unif (0.0027, 0.0041)
Monthly ART dropout rate (CD4<200), Male Hispanic MWID						
<i>PE</i>	0.0215	0.0181	0.0152	0.0215	0.0181	0.00340
<i>Distribution</i>	ln (-3.84, 0.1193)	ln (-4.01, 0.1516)	ln (-4.19, 0.2084)	ln (-3.84, 0.1193)	ln (-4.01, 0.1516)	Unif (0.0027, 0.0041)
Monthly ART dropout rate (CD4<200), Male Hispanic HET						
<i>PE</i>	0.0161	0.0139	0.0120	0.0161	0.0139	0.00516
<i>Distribution</i>	ln (-4.13, 0.0931)	ln (-4.27, 0.1027)	ln (-4.43, 0.1747)	ln (-4.13, 0.0931)	ln (-4.27, 0.1027)	Unif (0.0041, 0.0062)
Monthly ART dropout rate (CD4<200), Female White PWID						
<i>PE</i>	0.0314	0.0129	0.0241	0.0314	0.0129	0.00427
<i>Distribution</i>	ln (-3.46, 0.0987)	ln (-4.35, 0.149)	ln (-3.73, 0.177)	ln (-3.46, 0.0987)	ln (-4.35, 0.149)	Unif (0.0034, 0.0051)
Monthly ART dropout rate (CD4<200), Female White HET						
<i>PE</i>	0.0210	0.0106	0.0164	0.0210	0.0106	0.00340
<i>Distribution</i>	ln (-3.86, 0.0895)	ln (-4.55, 0.1348)	ln (-4.11, 0.1504)	ln (-3.86, 0.0895)	ln (-4.55, 0.1348)	Unif (0.0027, 0.0041)
Monthly ART dropout rate (CD4<200), Female Black PWID						
<i>PE</i>	0.0405	0.0156	0.0259	0.0405	0.0156	0.00427
<i>Distribution</i>	ln (-3.21, 0.0761)	ln (-4.16, 0.1174)	ln (-3.65, 0.1839)	ln (-3.21, 0.0761)	ln (-4.16, 0.1174)	Unif (0.0034, 0.0051)
Monthly ART dropout rate (CD4<200), Female Black HET						
<i>PE</i>	0.0272	0.0128	0.0177	0.0272	0.0128	0.00340
<i>Distribution</i>	ln (-3.61, 0.0581)	ln (-4.36, 0.0961)	ln (-4.04, 0.1538)	ln (-3.61, 0.0581)	ln (-4.36, 0.0961)	Unif (0.0027, 0.0041)
Monthly ART dropout rate (CD4<200), Female Hispanic PWID						
<i>PE</i>	0.0240	0.0170	0.0176	0.0240	0.0170	0.00427
<i>Distribution</i>	ln (-3.73, 0.1041)	ln (-4.07, 0.1338)	ln (-4.04, 0.2026)	ln (-3.73, 0.1041)	ln (-4.07, 0.1338)	Unif (0.0034, 0.0051)

Monthly ART dropout rate (CD4<200), Female Hispanic HET						
<i>PE</i>	0.0161	0.0139	0.0120	0.0161	0.0139	0.00340
<i>Distribution</i>	ln (-4.13, 0.0953)	ln (-4.27, 0.1026)	ln (-4.43, 0.1754)	ln (-4.13, 0.0953)	ln (-4.27, 0.1026)	Unif (0.0027, 0.0041)
NUMBER OF SEXUAL PARTNERS						
Monthly number of homosexual partners: White, low-risk MSM						
<i>PE</i>	0.174	0.174	0.174	0.174	0.174	0.174
<i>Distribution</i>	Gamma (133, 0.00131)	Gamma (133, 0.00131)	Gamma (133, 0.00131)	Gamma (133, 0.00131)	Gamma (133, 0.00131)	Gamma (133, 0.00131)
Monthly number of homosexual partners: Black low-risk MSM						
<i>PE</i>	0.213	0.213	0.213	0.213	0.213	0.213
<i>Distribution</i>	Gamma (26.5, 0.00806)	Gamma (26.5, 0.00806)	Gamma (26.5, 0.00806)	Gamma (26.5, 0.00806)	Gamma (26.5, 0.00806)	Gamma (26.5, 0.00806)
Monthly number of homosexual partners: Hispanic low-risk MSM						
<i>PE</i>	0.158	0.158	0.158	0.158	0.158	0.158
<i>Distribution</i>	Gamma (39.2, 0.00404)	Gamma (39.2, 0.00404)	Gamma (39.2, 0.00404)	Gamma (39.2, 0.00404)	Gamma (39.2, 0.00404)	Gamma (39.2, 0.00404)
Monthly number of homosexual partners: White, high-risk MSM						
<i>PE</i>	0.802	0.904	0.857	1.30	0.907	0.669
<i>Distribution</i>	Pert (3.23, 4.52)	Pert (2.55, 4.67)	Pert (3.35, 4.47)	Pert (3.32, 4.48)	Pert (3.23, 4.52)	Pert (3.14, 4.55)
Monthly number of homosexual partners: Black, high-risk MSM						
<i>PE</i>	0.457	0.665	0.633	1.06	0.603	0.558
<i>Distribution</i>	Pert (1.51, 4.37)	Pert (3.48, 4.40)	Pert (2.52, 4.67)	Pert (3.27, 4.50)	Pert (2.38, 4.67)	Pert (1.91, 4.57)
Monthly number of homosexual partners: Hispanic, high-risk MSM						
<i>PE</i>	0.72	0.932	0.725	1.04	0.817	0.757
<i>Distribution</i>	Pert (3.06, 4.58)	Pert (3.11, 4.57)	Pert (3.50, 4.38)	Pert (3.19, 4.54)	Pert (3.51, 4.38)	Pert (2.98, 4.61)
Monthly number of heterosexual partners: Male, White, low-risk MSM and MWID						
<i>PE</i>	0.0219	0.0219	0.0219	0.0219	0.0219	0.0219
<i>Distribution</i>	Gamma (31, 0.00071)	Gamma (31, 0.00071)	Gamma (31, 0.00071)	Gamma (31, 0.00071)	Gamma (31, 0.00071)	Gamma (31, 0.00071)
Monthly number of heterosexual partners: Male, White, low-risk HET						
<i>PE</i>	0.0883	0.0883	0.0800	0.0883	0.0883	0.0800
<i>Distribution</i>	Gamma (1248, 0.00007)	Gamma (1248, 0.00007)	Gamma (490, 0.00016)	Gamma (1248, 0.00007)	Gamma (1248, 0.00007)	Gamma (490, 0.00016)
Monthly number of heterosexual partners: Male, Black, low-risk MSM and MWID						
<i>PE</i>	0.0220	0.0220	0.0220	0.0220	0.0220	0.0220
<i>Distribution</i>	Gamma (13, 0.00176)	Gamma (13, 0.00176)	Gamma (13, 0.00176)	Gamma (13, 0.00176)	Gamma (13, 0.00176)	Gamma (13, 0.00176)
Monthly number of heterosexual partners: Male, Black, low-risk HET						
<i>PE</i>	0.110	0.110	0.105	0.110	0.108	0.105
<i>Distribution</i>	Gamma (697, 0.00016)	Gamma (697, 0.00016)	Gamma (68, 0.00155)	Gamma (697, 0.00016)	Gamma (152, 0.00071)	Gamma (68, 0.00155)
Monthly number of heterosexual partners: Male, Hispanic, low-risk MSM and MWID						
<i>PE</i>	0.0181	0.0181	0.0181	0.0181	0.0181	0.0181
<i>Distribution</i>	Gamma (6, 0.00282)	Gamma (6, 0.00282)	Gamma (6, 0.00282)	Gamma (6, 0.00282)	Gamma (6, 0.00282)	Gamma (6, 0.00282)
Monthly number of heterosexual partners: Male, Hispanic, low-risk HET						
<i>PE</i>	0.0842	0.0842	0.0867	0.0842	0.0908	0.0867
<i>Distribution</i>	Gamma (638, 0.00013)	Gamma (638, 0.00013)	Gamma (513, 0.00017)	Gamma (638, 0.00013)	Gamma (317, 0.00029)	Gamma (513, 0.00017)
Monthly number of heterosexual partners: Female, White, low-risk HET						
<i>PE</i>	0.0825	0.0825	0.0825	0.0825	0.0925	0.0825

<i>Distribution</i>	Pert (2.754, 4.654)	Pert (2.754, 4.654)	Pert (2.754, 4.654)	Pert (2.754, 4.654)	Pert (2.754, 4.654)	Pert (2.754, 4.654)
Transmission probability (CD4<200): Female to Male						
<i>PE</i>	0.0500	0.0500	0.0500	0.0500	0.0500	0.0500
<i>Distribution</i>	Pert (2.656, 4.666)	Pert (2.656, 4.666)	Pert (2.656, 4.666)	Pert (2.656, 4.666)	Pert (2.656, 4.666)	Pert (2.656, 4.666)
Transmission probability (CD4>500): Male to Female						
<i>PE</i>	0.0300	0.0300	0.0300	0.0300	0.0300	0.0300
<i>Distribution</i>	Pert (1.968, 4.592)	Pert (1.968, 4.592)	Pert (1.968, 4.592)	Pert (1.968, 4.592)	Pert (1.968, 4.592)	Pert (1.968, 4.592)
Transmission probability (CD4: 200-499): Male to Female						
<i>PE</i>	0.0500	0.0500	0.0500	0.0500	0.0500	0.0500
<i>Distribution</i>	Pert (4.443, 3.397)	Pert (4.443, 3.397)	Pert (4.443, 3.397)	Pert (4.443, 3.397)	Pert (4.443, 3.397)	Pert (4.443, 3.397)
Transmission probability (CD4<200): Male to Female						
<i>PE</i>	0.1000	0.1000	0.1000	0.1000	0.1000	0.1000
<i>Distribution</i>	Pert (4.27, 3.681)	Pert (4.27, 3.681)	Pert (4.27, 3.681)	Pert (4.27, 3.681)	Pert (4.27, 3.681)	Pert (4.27, 3.681)
TRANSMISSION PROBABILITY PER HOMOSEXUAL PARTNERSHIP						
Transmission probability (CD4>500)						
<i>PE</i>	0.045	0.045	0.045	0.045	0.045	0.045
<i>Distribution</i>	Pert (2.456, 4.673)	Pert (2.456, 4.673)	Pert (2.456, 4.673)	Pert (2.456, 4.673)	Pert (2.456, 4.673)	Pert (2.456, 4.673)
Transmission probability (CD4: 200-499)						
<i>PE</i>	0.065	0.065	0.065	0.065	0.065	0.065
<i>Distribution</i>	Pert (4.168, 3.814)	Pert (4.168, 3.814)	Pert (4.168, 3.814)	Pert (4.168, 3.814)	Pert (4.168, 3.814)	Pert (4.168, 3.814)
Transmission probability (CD4<200)						
<i>PE</i>	0.125	0.125	0.125	0.125	0.125	0.125
<i>Distribution</i>	Pert (4, 4)	Pert (4, 4)	Pert (4, 4)	Pert (4, 4)	Pert (4, 4)	Pert (4, 4)
TRANSMISSION PROBABILITY PER SHARED INJECTION						
Transmission probability (CD4>500)						
<i>PE</i>	0.0030	0.0030	0.0030	0.0030	0.0030	0.0030
<i>Distribution</i>	Pert (2.005, 4.604)	Pert (2.005, 4.604)	Pert (2.005, 4.604)	Pert (2.005, 4.604)	Pert (2.005, 4.604)	Pert (2.005, 4.604)
Transmission probability (CD4: 200-499)						
<i>PE</i>	0.0040	0.0040	0.0040	0.0040	0.0040	0.0040
<i>Distribution</i>	Pert (2.938, 4.617)	Pert (2.938, 4.617)	Pert (2.938, 4.617)	Pert (2.938, 4.617)	Pert (2.938, 4.617)	Pert (2.938, 4.617)
Transmission probability (CD4<200)						
<i>PE</i>	0.0060	0.0060	0.0060	0.0060	0.0060	0.0060
<i>Distribution</i>	Pert (1.4, 4.283)	Pert (1.4, 4.283)	Pert (1.4, 4.283)	Pert (1.4, 4.283)	Pert (1.4, 4.283)	Pert (1.4, 4.283)
HIV TESTING						
Monthly rate of symptom-based case finding (CD4: 200-499)						
<i>PE</i>	0.00874	0.00874	0.00874	0.00874	0.00874	0.00874
<i>Distribution</i>	Pert (3.86, 4.13)	Pert (3.86, 4.13)	Pert (3.86, 4.13)	Pert (3.86, 4.13)	Pert (3.86, 4.13)	Pert (3.86, 4.13)
Monthly rate of symptom-based case finding (CD4<200)						
<i>PE</i>	0.0184	0.0184	0.0184	0.0184	0.0184	0.0184
<i>Distribution</i>	Pert (3.84, 4.15)	Pert (3.84, 4.15)	Pert (3.84, 4.15)	Pert (3.84, 4.15)	Pert (3.84, 4.15)	Pert (3.84, 4.15)
Monthly rate of HIV testing/screening: Male White PWID						
<i>PE</i>	0.0363	0.0984	0.0426	0.0544	0.0764	0.0595
<i>Distribution</i>	Beta (35.7, 65.4)	Beta (45, 20)	Beta (99.1, 148.6)	Beta (109, 118)	Beta (154, 103)	Beta (194, 187)
Monthly rate of HIV testing/screening: Male White low-risk MSM						
<i>PE</i>	0.0112	0.0066	0.0066	0.0061	0.0313	0.0058

<i>Distribution</i>	Beta (18.2, 127)	Beta (13.1, 158.7)	Beta (133.7, 1618.2)	Beta (68.3, 903)	Beta (102, 225)	Beta (93, 1292)
Monthly rate of HIV testing/screening: Male White high-risk MSM						
<i>PE</i>	0.0974	0.0955	0.1108	0.0787	0.1304	0.0860
<i>Distribution</i>	Beta (59.8, 26.9)	Beta (52.3, 24.4)	Beta (131, 47.2)	Beta (119, 75.6)	Beta (129, 34.2)	Beta (103, 57.1)
Monthly rate of HIV testing/screening: Male White MWID						
<i>PE</i>	0.0363	0.0984	0.0426	0.0544	0.0764	0.0595
<i>Distribution</i>	Beta (35.7, 65.4)	Beta (45, 20)	Beta (99.1, 149)	Beta (108.7, 118)	Beta (154, 103)	Beta (194, 187)
Monthly rate of HIV testing/screening: Male White low-risk HET						
<i>PE</i>	0.0112	0.0066	0.0066	0.0061	0.0313	0.0058
<i>Distribution</i>	Beta (18.2, 127)	Beta (13.1, 158.7)	Beta (134, 1618)	Beta (68.3, 903)	Beta (102, 225)	Beta (93, 1292)
Monthly rate of HIV testing/screening: Male White high-risk HET						
<i>PE</i>	0.116	0.0457	0.0143	0.2496	0.0916	0.0160
<i>Distribution</i>	Beta (53.7, 17.9)	Beta (13.2, 18)	Beta (19.3, 103.1)	Beta (348, 18.3)	Beta (125, 62.4)	Beta (24.4, 115)
Monthly rate of HIV testing/screening: Male Black PWID						
<i>PE</i>	0.0642	0.0984	0.0647	0.0892	0.0946	0.0440
<i>Distribution</i>	Beta (17.8, 15.3)	Beta (12.5, 5.5)	Beta (3.9, 3.4)	Beta (13.6, 7.1)	Beta (12.6, 5.99)	Beta (1.8, 2.7)
Monthly rate of HIV testing/screening: Male Black low-risk MSM						
<i>PE</i>	0.0236	0.0206	0.0170	0.0101	0.0336	0.0218
<i>Distribution</i>	Beta (19.1, 58.4)	Beta (27.8, 99)	Beta (22.1, 97.7)	Beta (17.7, 137)	Beta (113, 228)	Beta (12.2, 40.8)
Monthly rate of HIV testing/screening: Male Black high-risk MSM						
<i>PE</i>	0.113	0.0955	0.1651	0.0971	0.101	0.0578
<i>Distribution</i>	Beta (17.1, 5.9)	Beta (14.5, 6.8)	Beta (6.1, 0.97)	Beta (12.1, 5.5)	Beta (11.5, 4.9)	Beta (1.6, 1.6)
Monthly rate of HIV testing/screening: Male Black MWID						
<i>PE</i>	0.0642	0.0984	0.0647	0.0892	0.0946	0.0440
<i>Distribution</i>	Beta (17.8, 15.3)	Beta (12.5, 5.5)	Beta (3.9, 3.4)	Beta (13.6, 7.1)	Beta (12.6, 5.99)	Beta (1.8, 2.7)
Monthly rate of HIV testing/screening: Male Black low-risk HET						
<i>PE</i>	0.0236	0.0206	0.0170	0.0101	0.0336	0.0218
<i>Distribution</i>	Beta (19.1, 58.4)	Beta (27.8, 99)	Beta (22.1, 97.7)	Beta (17.7, 137)	Beta (113, 228)	Beta (12.2, 40.8)
Monthly rate of HIV testing/screening: Male Black high-risk HET						
<i>PE</i>	0.0473	0.0457	0.0338	0.0470	0.0561	0.0207
<i>Distribution</i>	Beta (12.2, 16)	Beta (3.5, 4.8)	Beta (2.2, 4.4)	Beta (9.8, 12.9)	Beta (8.2, 8.5)	Beta (0.84, 2.98)
Monthly rate of HIV testing/screening: Male Hispanic PWID						
<i>PE</i>	0.0578	0.0984	0.0595	0.0719	0.116	0.0501
<i>Distribution</i>	Beta (1.6, 1.6)	Beta (4, 1.8)	Beta (58.1, 55.8)	Beta (5.3, 3.9)	Beta (9.1, 3.03)	Beta (22.1, 26.8)
Monthly rate of HIV testing/screening: Male Hispanic low-risk MSM						
<i>PE</i>	0.0441	0.0150	0.0075	0.0157	0.0366	0.0039
<i>Distribution</i>	Beta (5.3, 7.6)	Beta (4, 20)	Beta (73.4, 785)	Beta (16.5, 79.6)	Beta (123, 223)	Beta (4.98, 104)
Monthly rate of HIV testing/screening: Male Hispanic high-risk MSM						
<i>PE</i>	0.0512	0.0955	0.106	0.0799	0.132	0.0897
<i>Distribution</i>	Beta (1.4, 1.7)	Beta (4.2, 2)	Beta (58.7, 23)	Beta (4.9, 3)	Beta (9.9, 2.5)	Beta (13, 6.7)
Monthly rate of HIV testing/screening: Male Hispanic MWID						
<i>PE</i>	0.0578	0.0984	0.0595	0.0719	0.116	0.0501
<i>Distribution</i>	Beta (1.6, 1.6)	Beta (4, 1.8)	Beta (58.1, 55.8)	Beta (5.3, 3.9)	Beta (9.1, 3.03)	Beta (22.1, 26.8)
Monthly rate of HIV testing/screening: Male Hispanic low-risk HET						
<i>PE</i>	0.0441	0.0150	0.0075	0.0157	0.0366	0.0039

<i>Distribution</i>	Beta (5.3, 7.6)	Beta (4, 20)	Beta (73.4, 785)	Beta (16.5, 79.6)	Beta (123, 223)	Beta (4.98, 104)
Monthly rate of HIV testing/screening: Male Hispanic high-risk HET						
<i>PE</i>	0.0186	0.0457	0.0144	0.0338	0.0547	0.0219
<i>Distribution</i>	Beta (0.8, 3)	Beta (1.3, 1.8)	Beta (8.5, 45.4)	Beta (2.8, 5.6)	Beta (5.9, 6.4)	Beta (5.03, 16.8)
Monthly rate of HIV testing/screening: Female White PWID						
<i>PE</i>	0.0530	0.0911	0.0381	0.104	0.142	0.0485
<i>Distribution</i>	Beta (191, 214)	Beta (60, 30)	Beta (122, 210)	Beta (241, 96)	Beta (184, 41)	Beta (263, 333)
Monthly rate of HIV testing/screening: Female White low-risk HET						
<i>PE</i>	0.0060	0.0071	0.0055	0.0052	0.0257	0.0050
<i>Distribution</i>	Beta (21.7, 289)	Beta (42.6, 479)	Beta (130, 1916)	Beta (91.7, 1434)	Beta (133.9, 370)	Beta (112.3, 1814)
Monthly rate of HIV testing/screening: Female White high-risk HET						
<i>PE</i>	0.0426	0.0627	0.0969	0.0916	0.0916	0.0459
<i>Distribution</i>	Beta (135, 203)	Beta (58, 52)	Beta (189, 86)	Beta (247, 123)	Beta (176, 88)	Beta (160, 217)
Monthly rate of HIV testing/screening: Female Black PWID						
<i>PE</i>	0.0659	0.0911	0.0880	0.1083	0.116	0.0657
<i>Distribution</i>	Beta (53.2, 44.1)	Beta (8.5, 4.3)	Beta (6, 3.2)	Beta (8.1, 3.03)	Beta (20.8, 6.9)	Beta (2.96, 2.5)
Monthly rate of HIV testing/screening: Female Black low-risk HET						
<i>PE</i>	0.0191	0.0278	0.0185	0.0223	0.0356	0.0135
<i>Distribution</i>	Beta (40, 156)	Beta (61.4, 155)	Beta (34.2, 137)	Beta (43.1, 140)	Beta (190, 358)	Beta (6.7, 38)
Monthly rate of HIV testing/screening: Female Black high-risk HET						
<i>PE</i>	0.0446	0.0627	0.0402	0.0486	0.0508	0.0343
<i>Distribution</i>	Beta (34.2, 48.2)	Beta (8.2, 7.3)	Beta (3.2, 5.2)	Beta (6.4, 8.1)	Beta (13.2, 15.8)	Beta (1.5, 2.9)
Monthly rate of HIV testing/screening: Female Hispanic PWID						
<i>PE</i>	0.0034	0.0911	0.0609	0.0706	0.123	0.0372
<i>Distribution</i>	Beta (8, 192.7)	Beta (2.8, 1.4)	Beta (60.1, 55.8)	Beta (23, 17.2)	Beta (16.4, 4.9)	Beta (11.6, 20.6)
Monthly rate of HIV testing/screening: Female Hispanic low-risk HET						
<i>PE</i>	0.0024	0.0161	0.0112	0.0076	0.0407	0.0091
<i>Distribution</i>	Beta (1.2, 40)	Beta (6.5, 30.5)	Beta (154.5, 1078.8)	Beta (18.6, 194)	Beta (225, 357)	Beta (19.4, 168)
Monthly rate of HIV testing/screening: Female Hispanic high-risk HET						
<i>PE</i>	0.0764	0.0627	0.0251	0.0392	0.0603	0.0338
<i>Distribution</i>	Beta (86.7, 57.8)	Beta (1.8, 1.6)	Beta (20.7, 59)	Beta (14.6, 24.3)	Beta (12.2, 11.5)	Beta (6.5, 12.9)
Annual change in HIV testing rate						
<i>PE</i>	0.05	0.05	0.05	0.05	0.05	0.05
<i>Distribution</i>	Unif (0, 0.1)	Unif (0, 0.1)	Unif (0, 0.1)	Unif (0, 0.1)	Unif (0, 0.1)	Unif (0, 0.1)
QUALITY-ADJUSTED LIFE-YEAR WEIGHTS						
QALY weight for infected PLHIV (CD4>500)						
<i>PE</i>	0.91	0.91	0.91	0.91	0.91	0.91
<i>Distribution</i>	Pert (4.44, 3.4)	Pert (4.44, 3.4)	Pert (4.44, 3.4)	Pert (4.44, 3.4)	Pert (4.44, 3.4)	Pert (4.44, 3.4)
QALY weight for infected PLHIV (CD4: 200-499)						
<i>PE</i>	0.79	0.79	0.79	0.79	0.79	0.79
<i>Distribution</i>	Pert (4.17, 1.27)	Pert (4.17, 1.27)	Pert (4.17, 1.27)	Pert (4.17, 1.27)	Pert (4.17, 1.27)	Pert (4.17, 1.27)
QALY weight for infected PLHIV (CD4<200)						
<i>PE</i>	0.72	0.72	0.72	0.72	0.72	0.72
<i>Distribution</i>	Pert (4.59, 1.97)	Pert (4.59, 1.97)	Pert (4.59, 1.97)	Pert (4.59, 1.97)	Pert (4.59, 1.97)	Pert (4.59, 1.97)
QALY weight for diagnosed PLHIV (CD4>500)						

<i>PE</i>	0.865	0.865	0.865	0.865	0.865	0.865
<i>Distribution</i>	Pert (1.61, 4.43)	Pert (1.61, 4.43)	Pert (1.61, 4.43)	Pert (1.61, 4.43)	Pert (1.61, 4.43)	Pert (1.61, 4.43)
QALY weight for diagnosed PLHIV (CD4: 200-499)						
<i>PE</i>	0.72	0.72	0.72	0.72	0.72	0.72
<i>Distribution</i>	Pert (1.97, 4.59)	Pert (1.97, 4.59)	Pert (1.97, 4.59)	Pert (1.97, 4.59)	Pert (1.97, 4.59)	Pert (1.97, 4.59)
QALY weight for diagnosed PLHIV (CD4<200)						
<i>PE</i>	0.72	0.72	0.72	0.72	0.72	0.72
<i>Distribution</i>	Pert (4.59, 1.97)	Pert (4.59, 1.97)	Pert (4.59, 1.97)	Pert (4.59, 1.97)	Pert (4.59, 1.97)	Pert (4.59, 1.97)
QALY weight for treated PLHIV (CD4>500)						
<i>PE</i>	0.865	0.865	0.865	0.865	0.865	0.865
<i>Distribution</i>	Pert (1.611, 4.429)	Pert (1.611, 4.429)	Pert (1.611, 4.429)	Pert (1.611, 4.429)	Pert (1.611, 4.429)	Pert (1.611, 4.429)
QALY weight for treated PLHIV (CD4: 200-499)						
<i>PE</i>	0.83	0.83	0.83	0.83	0.83	0.83
<i>Distribution</i>	Pert (1.97, 4.59)	Pert (1.97, 4.59)	Pert (1.97, 4.59)	Pert (1.97, 4.59)	Pert (1.97, 4.59)	Pert (1.97, 4.59)
QALY weight for treated PLHIV (CD4<200)						
<i>PE</i>	0.82	0.82	0.82	0.82	0.82	0.82
<i>Distribution</i>	Pert (0.667, 3.33)	Pert (0.667, 3.33)	Pert (0.667, 3.33)	Pert (0.667, 3.33)	Pert (0.667, 3.33)	Pert (0.667, 3.33)
QALY weight adjusted for PWID						
<i>PE</i>	0.174	0.174	0.174	0.174	0.174	0.174
<i>Distribution</i>	Pert (4, 4)	Pert (4, 4)	Pert (4, 4)	Pert (4, 4)	Pert (4, 4)	Pert (4, 4)
QALY weight adjusted for opioid agonist therapy recipients						
<i>PE</i>	0.213	0.213	0.213	0.213	0.213	0.213
<i>Distribution</i>	Pert (3.7, 4.25)	Pert (3.7, 4.25)	Pert (3.7, 4.25)	Pert (3.7, 4.25)	Pert (3.7, 4.25)	Pert (3.7, 4.25)
HEALTH CARE COSTS FOR PLHIV RECEIVING ART						
Health care cost (CD4>500): Male PWID						
<i>PE</i>	4559	4219	4604	4559	4219	4604
<i>Distribution</i>	Gamma (6301, 2.17)	Gamma (6511, 1.94)	Gamma (5048, 2.74)	Gamma (6301, 2.17)	Gamma (6511, 1.94)	Gamma (5048, 2.74)
Health care cost (CD4>500): Male MSM						
<i>PE</i>	3784	3503	3821	3784	3503	3821
<i>Distribution</i>	Gamma (24395, 0.47)	Gamma (28851, 0.36)	Gamma (15423, 0.74)	Gamma (24395, 0.47)	Gamma (28851, 0.36)	Gamma (15423, 0.74)
Health care cost (CD4>500): Male MWID						
<i>PE</i>	4173	3862	4214	4173	3862	4214
<i>Distribution</i>	Gamma (3013, 4.15)	Gamma (3027, 3.83)	Gamma (2989, 4.23)	Gamma (3013, 4.15)	Gamma (3027, 3.83)	Gamma (2989, 4.23)
Health care cost (CD4>500): Male HET						
<i>PE</i>	3951	3657	3990	3951	3657	3990
<i>Distribution</i>	Gamma (14940, 0.79)	Gamma (14297, 0.77)	Gamma (9092, 1.32)	Gamma (14940, 0.79)	Gamma (14297, 0.77)	Gamma (9092, 1.32)
Health care cost (CD4>500): Female PWID						
<i>PE</i>	4781	4425	4828	4781	4425	4828
<i>Distribution</i>	Gamma (3594, 3.99)	Gamma (3615, 3.67)	Gamma (3142, 4.61)	Gamma (3594, 3.99)	Gamma (3615, 3.67)	Gamma (3142, 4.61)
Health care cost (CD4>500): Female HET						
<i>PE</i>	4090	3786	4130	4090	3786	4130
<i>Distribution</i>	Gamma (17345, 0.71)	Gamma (16692, 0.68)	Gamma (9559, 1.3)	Gamma (17345, 0.71)	Gamma (16692, 0.68)	Gamma (9559, 1.3)
Health care cost (CD4: 200-499): Male PWID						
<i>PE</i>	4620	4277	4666	4620	4277	4666

<i>Distribution</i>	Gamma (6362, 2.18)	Gamma (6526, 1.97)	Gamma (5072, 2.76)	Gamma (6362, 2.18)	Gamma (6526, 1.97)	Gamma (5072, 2.76)
Health care cost (CD4: 200-499): Male MSM						
<i>PE</i>	3835	3550	3873	3835	3550	3873
<i>Distribution</i>	Gamma (24477, 0.47)	Gamma (28010, 0.38)	Gamma (15325, 0.76)	Gamma (24477, 0.47)	Gamma (28010, 0.38)	Gamma (15325, 0.76)
Health care cost (CD4: 200-499): Male MWID						
<i>PE</i>	4229	3914	4271	4229	3914	4271
<i>Distribution</i>	Gamma (3020, 4.2)	Gamma (3024, 3.88)	Gamma (2991, 4.28)	Gamma (3020, 4.2)	Gamma (3024, 3.88)	Gamma (2991, 4.28)
Health care cost (CD4: 200-499): Male HET						
<i>PE</i>	4004	3706	4044	4004	3706	4044
<i>Distribution</i>	Gamma (15199, 0.79)	Gamma (14288, 0.78)	Gamma (9140, 1.33)	Gamma (15199, 0.79)	Gamma (14288, 0.78)	Gamma (9140, 1.33)
Health care cost (CD4: 200-499): Female PWID						
<i>PE</i>	4845	4485	4893	4845	4485	4893
<i>Distribution</i>	Gamma (3595, 4.04)	Gamma (3602, 3.74)	Gamma (3137, 4.68)	Gamma (3595, 4.04)	Gamma (3602, 3.74)	Gamma (3137, 4.68)
Health care cost (CD4: 200-499): Female HET						
<i>PE</i>	4145	3837	4186	4145	3837	4186
<i>Distribution</i>	Gamma (17205, 0.72)	Gamma (16243, 0.71)	Gamma (9466, 1.33)	Gamma (17205, 0.72)	Gamma (16243, 0.71)	Gamma (9466, 1.33)
Health care cost (CD4<200): Male PWID						
<i>PE</i>	4928	4561	4977	4928	4561	4977
<i>Distribution</i>	Gamma (5983, 2.47)	Gamma (6089, 2.25)	Gamma (4815, 3.1)	Gamma (5983, 2.47)	Gamma (6089, 2.25)	Gamma (4815, 3.1)
Health care cost (CD4<200): Male MSM						
<i>PE</i>	4091	3786	4131	4091	3786	4131
<i>Distribution</i>	Gamma (18905, 0.65)	Gamma (20517, 0.55)	Gamma (12845, 0.96)	Gamma (18905, 0.65)	Gamma (20517, 0.55)	Gamma (12845, 0.96)
Health care cost (CD4<200): Male MWID						
<i>PE</i>	4511	4175	4555	4511	4175	4555
<i>Distribution</i>	Gamma (2921, 4.63)	Gamma (2916, 4.3)	Gamma (2889, 4.73)	Gamma (2921, 4.63)	Gamma (2916, 4.3)	Gamma (2889, 4.73)
Health care cost (CD4<200): Male HET						
<i>PE</i>	4271	3953	4313	4271	3953	4313
<i>Distribution</i>	Gamma (13136, 0.98)	Gamma (12299, 0.96)	Gamma (8314, 1.56)	Gamma (13136, 0.98)	Gamma (12299, 0.96)	Gamma (8314, 1.56)
Health care cost (CD4<200): Female PWID						
<i>PE</i>	5168	4783	5219	5168	4783	5219
<i>Distribution</i>	Gamma (3455, 4.49)	Gamma (3449, 4.16)	Gamma (3025, 5.18)	Gamma (3455, 4.49)	Gamma (3449, 4.16)	Gamma (3025, 5.18)
Health care cost (CD4<200): Female HET						
<i>PE</i>	4421	4092	4465	4421	4092	4465
<i>Distribution</i>	Gamma (14313, 0.93)	Gamma (13461, 0.91)	Gamma (8481, 1.58)	Gamma (14313, 0.93)	Gamma (13461, 0.91)	Gamma (8481, 1.58)

PE: point estimate; PLHIV: people living with HIV; PWID: people who inject drugs; MSM: men who have sex with men; MWID: men who are both MSM and PWID; HET: heterosexual; ln: lognormal; Unif: uniform; QALY: quality-adjusted life year.